Press Releases

BETHESDA, Md., March 17, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $7.5 million. In the transaction, the Company will sell approximately 28.8 million shares of common stock at a... Read More

BETHESDA, MD, March 10, 2017 – Northwest Biotherapeutics, Inc. (OTCQB: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that it has signed a Note Repurchase Agreement with a group of bondholders affiliated with Whitebox Advisors (“Whitebox”), holder of $11 million of NW Bio convertible senior notes. With these Notes otherwise... Read More

Process Now Moving Forward Toward Data Lock   BETHESDA, Md., February 6, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio” or the “Company”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided a further update about the Company’s Phase III trial of DCVax®-L for Glioblastoma multiforme (“GBM”) brain cancer (the “Trial”).  The Company announced that the partial... Read More

BETHESDA, MD, January 18, 2017 – Northwest Biotherapeutics, Inc. (OTCQB: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that Dr. Marnix Bosch, Chief Technical Officer of NW Bio, will present at the Phacilitate Immunotherapy World Conference on Thursday, January 19, 2017, at the Hyatt Regency Hotel in Miami, Florida. Dr.... Read More

BETHESDA, Md., December 19, 2016 – Northwest Biotherapeutics (Nasdaq: NWBO) (“NW Bio” or the “Company”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that its common stock will begin trading on the OTC Market Group’s OTCQB marketplace effective at the open of the market on Monday, December 19, 2016.  The Trading symbol will remain NWBO. As of this morning, t... Read More